PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.63%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.63%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is 1.11%. Seth Klarman would investigate advantages.
-72.63%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is 0.21%. Seth Klarman would investigate advantages.
105.80%
Interest expense change of 105.80% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
72.63%
EBITDA change of 72.63% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
72.63%
Operating income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
105.80%
Other expenses change of 105.80% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
73.70%
Income change of 73.70% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
73.70%
Net income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
80.46%
EPS change of 80.46% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
80.46%
Diluted EPS change of 80.46% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
33.82%
Share count change of 33.82% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
33.82%
Diluted share change of 33.82% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.